Tumor-specific autoantibodies for SCLC early detection
This project proposes to leverage molecular features unique to SCLC, such as the development of autoantibodies, to validate a plasma biomarker panel capable of SCLC early detection to allow for early initiation of potentially curative chemotherapy.
NIH R01 CA243328, MPI: Houghton/Lampe
Active Dates
12/17/2019 to 11/30/2024
Faculty Involved